CrowdStrike Falcon Fund Invests and Forms Partnership with Aembit to Help Drive Identity Security through Workload Identity and Access Management

SILVER SPRING, Md., Oct. 31, 2023 — Aembit, the Workload Identity and Access Management (IAM) Company, today announced an investment by CrowdStrike, via its strategic investment vehicle, the CrowdStrike Falcon Fund. CrowdStrike’s investment closes Aembit’s previously announced seed funding round from Ballistic Ventures, Ten Eleven Ventures, and Okta Ventures. As part of that investment, Aembit and CrowdStrike will partner on a technical integration with go-to-market alignment. This partnership will help provide customers with a comprehensive Zero Trust strategy by assessing the identity and health of workloads before permitting access to sensitive resources.

“Zero Trust principles are beginning to influence workload-to-workload deployments, similar to how they influence user access to resources,” said David Goldschlag, CEO and co-founder of Aembit. “The combination of workload identity, risk assessment, and policy-based access allows enterprises to provide sophisticated identity security across their applications without burdening their development and operations teams. We are excited to be partnering with CrowdStrike to bring Aembit’s Workload IAM approach to the enterprise.”

Enterprise applications are becoming more distributed, as they include software the enterprise develops, databases, and APIs from customers and partners. Despite this complexity, many companies rely on secrets and secret managers for workload-to-workload access which are brittle, hard to manage, and do not allow for the creation, enforcement, and auditing of workload access policies. Furthermore, while workloads have identities and continually changing security postures as users do, the technical means and workflows to manage them are radically different.

To solve this, Aembit has pioneered one of the first cloud services for workload identity and access management (IAM). Aembit cryptographically identifies workloads based on a range of characteristics including attestation, assesses their security posture, and defines conditional access policies that determine workload access rights. Aembit also eliminates static workload identity secrets, removes the need for developers to code workload-to-workload authorization, and makes it easy to centralize visibility and control. With Aembit, enterprises manage access, not secrets.

“Identity is a critical pillar to securing the modern enterprise at each layer of the stack,” said Gur Talpaz, vice president of corporate development at CrowdStrike and head of Falcon Fund. “As cloud adoption has proliferated, the complexity associated with managing federated workloads at each layer has become daunting and resulted in significant exposure. Aembit enables enterprises to take control of their machine identity access management and scale their security programs within their rapidly expanding cloud estate. We are excited to partner with the Aembit team to bring joint solutions to our customers.”

The CrowdStrike Falcon Fund is a cross-stage investment fund and the largest corporate venture arm in the cybersecurity industry. The program is designed to build an ecosystem of next-generation security leaders that share a common mission through a unique combination of investment and deep technical integrations with the CrowdStrike Falcon platform, giving CrowdStrike customers access to cutting-edge third-party capabilities.

Enterprises can learn more about and begin using Aembit for free at www.aembit.io.

Contacts

Aembit:
Apurva Dave
[email protected] 

About Aembit

Aembit is the Workload Identity Platform that lets every business safely build its next generation of applications by inherently trusting how it connects to partners, customers, and foundational services. Aembit provides seamless and secure access from your workloads to the services they depend on, like APIs, databases, and cloud resources, while simplifying application development, delivery, compliance, and audit.

Learn: Website

Follow:  LinkedIn | Twitter

Use: Free Forever Tier

SOURCE Aembit

WOBURN, Mass., Oct. 31, 2023 — iQ3Connect, a provider of a web-based immersive training and collaboration platform, today announced a seed round of funding through the NOVA Prime Fund, a venture capital fund created by global innovator LG Electronics.

iQ3Connect provides a web-based solution that empowers individuals, teams and enterprises to create, deploy, collaborate and learn with immersive and interactive 3D content on any VR, AR, PC or mobile device. Transforming immersive 3D into a scalable tool for enterprises, iQ3Connect offers a Training and Experience Platform that enables companies to rapidly create and deploy interactive virtual training and an Immersive Collaboration Platform, which provides a multi-user virtual workspace for companies. iQ3Connect also offers a host of services, from training and experience creation to hosting and management.

The NOVA Prime Fund is focused on investing in mission-driven companies innovating in sustainable energy, digital health, and industries of the future. LG NOVA, LG Electronics’ North America Innovation Center, serves as a contributing source to the NOVA Prime Fund for investments as a part of its Mission for the Future program, an initiative to build the future through cross-industry collaboration between startups and LG. As part of this investment, Jinhwan An from the LG NOVA team will join the iQ3Connect board of directors.

“The NOVA Prime Fund is committed to accelerating innovation for good to build a better future for people,” said Ali Diallo, Managing Partner at NOVA Prime Fund. “This strategic investment will help iQ3Connect advance their mission to help companies use their 3D platform and the metaverse to sustainably train the workforce of the future.”

“We share LG’s vision for the future,” said Ali Merchant, CEO of iQ3Connect. “Through our technology, our customers are advancing innovation at scale to make their organizations more efficient, sustainable, and competitive. Thanks to NOVA Prime Fund and their investment, even more organizations will be able to take advantage of the opportunity our 3D immersive platform offers.”

Founded in 2017, iQ3Connect is already deployed in numerous Global 2000 companies. As an example, a world leader in semiconductor and display manufacturing equipment is using iQ3Connect for customer support, manufacturing technician training, and knowledge transfer between different locations. They have trainers/SMEs creating and using multi-user virtual classrooms for training at scale.

One of the world’s largest oilfield services companies is scaling iQ3Connect for remote meetings for design and manufacturing teams and on-site construction planning, as well as operations and safety training for employees. Additionally, the Yokogawa Bridge Corporation, one of Japan’s top five fabricators and erectors of steel structures for bridges and buildings, uses a full-scale 3D bridge model with the iQ3Connect Platform to enable structure and design reviews in immersive 3D.

“We believe in the power of immersive technology to reshape the training industry, and iQ3Connect is at the forefront of this revolution,” said Ella Hood, Managing Director of Cherrystone Angel Group, an early investor in iQ3Connect. “Their web-based platform is versatile, scalable and addresses critical pain points in corporate training and team collaboration. As businesses worldwide prioritize upskilling their workforce, iQ3Connect’s Training and Experience Platform is poised for widespread adoption, presenting an immense growth opportunity.”

About NOVA Prime Fund
NOVA Prime Fund is a venture capital fund with a target of more than $100M and an objective of investing in private companies focused on clean energy, digital health, immersive AI, and industries of the future. The Fund will invest in high-growth technology companies and seek to accelerate them in collaboration with LG NOVA. Aligned on innovating for a better life, NOVA Prime Fund’s portfolio companies will be predominantly sourced from the Mission for the Future corporate acceleration program, led by LG NOVA, LG Electronics North America Center of Innovation. NOVA Prime Fund will focus on investing in mission-driven companies working towards solutions for a sustainable future for people and the planet.

About iQ3Connect
iQ3Connect provides a web-based solution empowering individuals, teams, and enterprises to create, deploy, collaborate, and learn with immersive and interactive 3D content on any VR, AR, PC, or mobile device. iQ3Connect is on a mission to transform immersive 3D into a scalable and pervasive communication tool for enterprises to save time, reduce cost, and achieve sustainable operations. www.iq3connect.com

SOURCE iQ3Connect

• Partnership with VeDA enhances Spiral’s commitment to patient outreach and education, while gaining invaluable insights from the VeDA Patient Registry

SAN FRANCISCO, Oct. 31, 2023 — Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage pharmaceutical company leading the way in therapies for inner ear disorders, today announced a strategic partnership with the Vestibular Disorders Association (VeDA). This alliance aims to improve the lives of patients suffering from balance disorders like Meniere’s Disease through targeted outreach, collaborative patient education programs, and data-driven research.

“Joining forces with VeDA is a significant milestone for Spiral, as it aligns with our commitment to address the unmet medical needs in the field of inner ear disorders,” said Hugo Peris, CEO of Spiral Therapeutics. “We’re honored to support VeDA’s mission and excited about the opportunity to significantly improve patient lives.”

“VeDA is honored to partner with Spiral in our mutual effort to support Meniere’s patients on their journey back to balance,” said Cynthia Ryan, Executive Director of VeDA. “We’re excited about the potential their new treatment offers to improve the lives of people struggling with vertigo, hearing loss, and tinnitus.”

This collaboration grants Spiral access to VeDA’s Patient Registry on Meniere’s patients, enriching its ongoing research efforts. Additionally, VeDA will facilitate targeted outreach to Meniere’s clinicians and patients in the United States and Australia. Both organizations will also collaborate on educational programs to further patient understanding of treatment nuances such as the placebo effect.

Ongoing Clinical Progress
Spiral continues to advance its inner ear programs, including its lead candidate SPT-2101 for Meniere’s Disease. The data from SPT-2101’s open label trial in Australia continues to support the safety and superior efficacy of Spiral’s proprietary drug delivery platform. Encouraged by these milestones, Spiral plans to submit an Investigational New Drug (IND) application for SPT-2101 in the United States in 2024.

About Spiral Therapeutics
Spiral Therapeutics is a clinical-stage company focused on delivering therapies for inner ear disorders. Spiral’s novel drug delivery platform allows for minimally invasive, precise and durable exposure of drugs to the cochlea. Spiral is advancing a therapeutic pipeline with focus on hearing loss and balance disorders. Spiral’s lead program, SPT-2101, is a long-acting steroid formulation for the treatment of inner ear inflammation. For more information, visit: www.spiraltx.com

About the Vestibular Disorders Association (VeDA)
The Vestibular Disorders Association is a global organization committed to providing support, education, and advocacy to vestibular patients and the healthcare professionals who treat them. For more information, visit: www.vestibular.org

Media Contacts 
For Spiral:
Hugo Peris, CEO ([email protected])
(650) 453-0893

For VeDA:
Cynthia Ryan, Executive Director ([email protected])
(503) 294-9085

SOURCE Spiral Therapeutics, Inc.

Funding to advance key research and commercialization initiatives across company’s three core platforms: Oral Delivery, Therapeutics, and Regenerative Medicine

PITTSBURGH, Oct. 31, 2023 — Imagine Pharma, a biotech company focused on furthering the commercialization opportunities related to its novel IMG-1 polypeptide, today announced that it has raised a $32.5 million Series A round, with an initial traunch of $10 million, bringing its total funding to date to $40 million. The round was led by IP Investors LLC, a group of seasoned investors that focuses on biotech companies that have attainable solutions for unmet medical needs. John T. Callaghan, CPA CFE, representing the investor group, will join the board. The funding will be used to advance the company’s priority programs in regenerative medicine, oral delivery, and therapeutics.

“I am thrilled by the exceptional interest during our raise and by the composition of our investor syndicate,” said Santiago Pujadas, co-CEO of Imagine Pharma. “I am looking forward to working with our team to continue building on our progress to date.”

Imagine Pharma discovered a novel polypeptide, IMG-1, that has led to significant scientific achievements that promise first-in-kind treatments across multiple underserved disease states. 

Specific programs to be funded through this investment include:

• Commercialization of a novel nutritional supplement
• Completion of pre-clinical studies and IND submittal for oral erythropoietin and glucagon-like peptide-1 (GLP-1) receptor agonists
• Advancement of AIPC research collaboration with LyGenesis
• Further expansion of the company’s islet isolation services business
• Strategic partnership development across all platforms

“Our scientific exploration and program development journeys are guided by science and the opportunities that it presents for us. This approach has led to a unique oral delivery system for biologics, a novel nutritional supplement with the potential to address numerous health and wellness issues, and the ability to regenerate and propagate different progenitor body cell-types, which could hold the key to developing cures for a myriad of disease states,” said Dr. Ngoc Thai, Founder, co-CEO, and Chief Medical Officer.

“We are constantly vetting biotech investment opportunities and are very excited about the uniqueness of Imagine Pharma, the milestones it has accomplished to-date, and the potential it holds,” said John Callaghan, member of IP Investors. “It is rare to find a biotech venture at this stage with such a broad array of partnership, licensing, and spinoff paths, as well as near-term revenue potential.”

About Imagine Pharma
Imagine Pharma is a biotechnology company focused on the development of its IMG-1 polypeptide. Research and development efforts have led to the development of three distinctive platforms for Oral Delivery, Therapeutics, and Regenerative Medicine, each with first-in-class programs that address multiple disease states in large, underserved markets. Imagine Pharma is an approved Islet Isolation Center for the National Institute of Diabetes and Digestive and Kidney Diseases Integrated Islet Distribution Program. Imagine Pharma was founded in 2016. For more information visit: www.imaginepharma.com.

Media Contact:
Jennifer Moritz
[email protected]

SOURCE Imagine Pharma

The new funding round was led by Clear Ventures and will accelerate the expansion of Espresa’s LSA Plus™ platform, modernizing personal benefits for global enterprises.

PALO ALTO, Calif., Oct. 31, 2023 — Espresa, a personal benefits platform designed for global enterprises, announced the completion of its Series A funding round totaling $23 million led by Clear Ventures. All existing investors participated, including Crosslink Capital, New Era Capital Partners, Moneta Venture Capital, Ridge Ventures and Westwave Capital. The new investment enables scaling and expanding sales and marketing, platform development, and further building the global support infrastructure.

Espresa’s personal benefits platform is engineered to help HR and Benefits teams streamline and modernize their offerings. The company’s unique approach — LSA Plus — blends traditional well-being benefits with Lifestyle Spending Accounts (LSA), which allows organizations to offer incentives for health-related and cultural activities. By directing existing funding to an LSA Plus program, employers can drive employee engagement and personalized well-being. Espresa optimizes budget allocation and simplifies the overall benefits landscape, enhancing the employee experience and bringing cohesion to HR strategies. As a mobile-first platform, organizations can engage employees wherever they live and however they work — in office, hybrid or remote.

Through the platform, employees can select meaningful and personal benefits for their life journey. Espresa allows access to LSA funds via payroll reimbursement, integrated marketplace or a pre-funded Espresa debit card. This unparalleled flexibility has resulted in industry record employee participation as high as 94%.

“Espresa solves multiple critical problems for human resource and people teams,” said Alex Shubat, co-founder and CEO of Espresa. “Until recently, HR was trapped in too many point solutions, budget consolidation needs and a lack of employee engagement with the legacy benefits they offer. We’re changing how people experience their benefits with a mobile-first platform that can change with the evolution of a company while being globally inclusive.”

CTO and co-founder Raghavan Menon added, “Espresa redefines what is possible for a global population with a personal benefits technology platform. Employees get an effortless experience with the flexibility to choose benefits that truly matter to them, while employers gain a streamlined solution that easily fits into their existing HR infrastructure. With a presence in over 80 countries, support for local currencies and availability in more than 100 languages, global is our DNA.”

Espresa has served hundreds of thousands of users on the platform across diverse sectors spanning tech, consumer, healthcare and pharma, financial services, media, agriculture, law, manufacturing and construction. Companies like Avalara, Cadence, Flex, Nielsen, Jazz Pharmaceuticals, Prudential, Unisys and The Wonderful Company use Espresa’s global platform to modernize their benefits offerings and improve employee experiences.

Clear Ventures’ founding partner, Chris Rust, said, “We focus on finding portfolio companies that redefine what is possible. HR tech, the future of work and reimagining the benefits landscape with personal benefits that connect companies with their culture are precisely what Espresa does. While their roadmap is highly focused, their ability to develop exceptional technology to meet clients’ collective needs is beyond a sprint. It’s a marathon, and they do it expertly.”

Espresa added luminary investor and founder of NEA Dick Kramlich and strategic EU-based London Technology Club (LTC) to its roster. Creating the critical shift in connective and global personal benefits, Espresa continues to grow thoughtfully and gain traction as a leading force in this space, this new funding brings the total raised to date to $30 million.

About Espresa, Inc.
Espresa, Inc. is Powering Great Workplaces® with personal benefits people love. The globally available LSA Plus™ platform consolidates physical, emotional, and financial well-being and family care benefits. Now, employers can incentivize wellness with activities that drive well-being pillars and promote recognition, community, and culture. Espresa was co-founded by Alex Shubat, CEO, and Raghavan Menon, CTO, in Palo Alto, California.

For more information, visit espresa.com.

SOURCE Espresa

PHOENIX, Oct. 31, 2023 — Trinity Capital Inc. (NASDAQ: TRIN) (“Trinity”), a leading provider of diversified financial solutions to growth-stage companies, today announced the commitment of $25 million in growth capital to Neuros Medical, Inc., a bioelectric technology company focused on alleviating chronic post-amputation pain and restoring quality of life.

Neuros Medical’s Altius System incorporates the company’s patented platform technology, On-Demand Bioelectric Nerve Block, which patients initiate as needed for targeted pain relief. The technology blocks sensory nerves and has the potential to alleviate pain in nearly one million Americans with phantom limb and residual limb pain, fulfilling a significant need for patients. This system also has the potential to reduce drug dependency as existing treatment options are primarily limited to opioids and gabapentinoids.

Rob Lake, Senior Managing Director, Life Sciences at Trinity, said, “We are proud to partner with Neuros Medical on their journey to improve the lives of those suffering from chronic post-amputation pain, and we look forward to working with their team to support their continued growth.”

The growth capital will enable Neuros Medical to augment the recent equity raised and further scale operations to assist with their commercial launch.

David Veino, President and Chief Executive Officer of Neuros Medical said, “We appreciate the conviction Trinity has in the Neuros mission and our ability to scale commercialization, delivering this life-changing therapy to a large, underserved amputee population in desperate need of pain relief.”

About Trinity Capital Inc.
Trinity Capital Inc. (Nasdaq: TRIN), an internally managed business development company, is a leading provider of diversified financial solutions to growth-stage companies with institutional equity investors. Trinity Capital’s investment objective is to generate current income and, to a lesser extent, capital appreciation through investments, including term loans and equipment financings and equity-related investments. Trinity Capital believes it is one of only a select group of specialty lenders that has the depth of knowledge, experience and track record in lending to growth stage companies. For more information, please visit the Company’s website at www.trinitycap.com.

About Neuros Medical, Inc.
Neuros Medical, a bioelectric technology company, has developed the Altius system for the treatment of chronic post-amputation pain (Phantom Limb Pain and Residual Limb Pain). Altius incorporates the Company’s patented platform technology, On-Demand Bioelectric Nerve Block. Patients initiate a 30-minute Altius treatment session as needed for targeted pain relief.

Neuros’ technology delivers a bioelectric signal to sensory nerves in the peripheral nervous system to block the pain signal. The system consists of a nerve cuff electrode (also known as a lead) placed around a peripheral nerve and an implantable pulse generator (IPG).

Chronic pain is characterized as pain lasting more than 3 months in duration. Post-amputation pain includes both phantom limb and residual limb (or “stump”) pain, and impacts nearly one million Americans. There are nearly two million amputees in the U.S., with 185,000 new amputations occurring every year. Post-amputation pain represents a significant unmet medical need, as existing treatment options are limited and consist primarily of opioids and gabapentinoids.

For more information, please visit www.neurosmedical.com. 

SOURCE Trinity Capital Inc.

The Israeli startup raised the first $13 million in April 2023 in a round led by Aescuvest, which led this extension as well. Foxconn Technology joined.

JERUSALEM, Israel, Oct. 31, 2023 — Neteera Technologies Ltd., an Israeli-based startup disrupting the contactless patient monitoring market, today announced the successful closing of a ~$6,7M Series B extension. The round was led by Aescuvest, a renowned healthcare investment firm, alongside Foxconn Technology Co., Ltd. (FTC), an associate of Hon Hai Precision Industry Co., Ltd., the largest electronics manufacturer globally.

The funds of this extension round will be used to expedite production, meet the increasing demand for Neteera’s platform, and to recruit more installation and deployment personnel. This significant step will allow Neteera to further solidify its leadership in the contactless patient monitoring market.

Partnering with Foxconn Technology Group, the world’s leading company and powerhouse in the electronics manufacturing market, will further boost Neteera’s international growth. A cooperation to produce Neteera’s products is already under way, with further business and technology collaborations in the pipeline.

“Neteera is an excellent medical equipment development company. We are delighted to participate in Neteera’s current round of funding and to become their manufacturing partner, providing strong support for the mass production of their products,” said William Hung, Chief Investment Officer at FTC.

In the face of challenging market conditions and VC funding slowdowns, Neteera has not only persevered but thrived. The startup’s big pull is its proven product-market-fit for a globally applicable problem, coupled with essential regulatory approvals, such as the FDA stamp.

“Neteera successfully tackles a problem that we are all prone to. Our ageing populations deserve professional, humane care. Technological solutions such as Neteera’s platform are a suitable answer to combat the problems of our healthcare systems,” said Sebastian Gührs, Partner & Head of Investment at Aescuvest.

Founded in 2015, Neteera quickly gained recognition for its FDA-cleared remote patient monitoring platform, designed to enable continuous monitoring of patients’ biomarkers without the need for contact or patient involvement. The platform is improving patient care and operator efficiencies all over the globe.

Outside of raising money, Neteera has been working on expanding access to its contactless patient monitoring platform. In 2023, the company began selling its solution to a large number of long-term care facilities in the US and has a significant pipeline of ordered products that are currently being deployed.

“We are proud to partner with such a renowned company as Foxconn to further expand our offering,” said Isaac Litman, CEO of Neteera. “This funding and cooperation will expedite our solution production and deployment, opening doors and allowing us to get one step closer to achieving our mission: saving life, improving patient care while reducing the burden on clinical staff.“

About Aescuvest:

Aescuvest is a healthcare investment company that focuses on funding digital healthcare ventures to make a significant impact. As the operator of a dedicated investment platform, the company offers exclusive access to promising healthcare ventures and facilitates direct investments through SPV structures. By providing entrepreneurial investments in a thriving market, Aescuvest enables investors to participate in lucrative healthcare investment opportunities.

About FTC:

Foxconn Technology Co., Ltd., an associate of Hon Hai Precision Industry Co., Ltd., was established in Taiwan in 1990. FTC is positioned as a professional ODM manufacturer whose products & expertise include system assembly of 3C products, mechanical design, processing, and sales. It provides global customers with complete design capacity, fast volume manufacturing capability, and efficient customer service. In recent years, Foxconn Technology has diversified its portfolio, delving into the medical device CDMO sector, robotics, and electric vehicles. With a reputation built on precision and innovation, the company continues to evolve, meeting the demands of modern industries and setting benchmarks in technology and beyond.

About Neteera:

Neteera’s FDA-cleared continuous, contactless, passive vital signs and bio-data monitoring solution provides better patient monitoring both for the crisis ridden healthcare system and home health. Our sensing platform eliminates the need for device manipulation, removal of clothing, and caregiver presence. Neteera’s technology is a based on a safe, maintenance-free, sub-THZ micro-radar on chip sensor solution that protects privacy as it is not based on a camera. We improve care and ultimately reduce healthcare costs by enabling optimal comfort for patients.

Media Contact: Sebastian Gührs
Head of Investment
Aescuvest
+491744333221
sebastian.guehrs@aescuvest.eu

Acuvest Logo : https://mma.prnewswire.com/media/2058115/Aescuvest_Logo.jpg
Neteera Logo: https://mma.prnewswire.com/media/2058117/Neteera_Logo.jpg
Foxconn Logo: https://mma.prnewswire.com/media/2258686/Foxconn_Logo.jpg

SOURCE Aescuvest

Both Nordic and international investors were attracted by Sigrid’s natural, non-drug alternative SiPore® technology

STOCKHOLM, Oct. 31, 2023 — Sigrid Therapeutics successfully secured $4 million in an oversubscribed funding round. The investment, made by both existing and new investors, underlines the strong investor confidence in Sigrid’s innovative SiPore® technology.

The funds will be instrumental in accelerating the commercialisation of SiPore® across diverse markets, including medical devices, food supplements, veterinary, and oral health. SiPore21®, the company’s flagship product, is currently undergoing SHINE clinical trials as a natural, non-drug solution for prediabetes progression and weight control. Administered orally, SiPore21® utilises a carefully engineered, mesoporous silica mineral to prevent digestive enzymes from breaking down carbohydrates and fats, offering a promising alternative to pharmaceutical methods.

“This funding will propel our efforts in establishing key partnerships and driving SiPore® technology to market. We are thrilled to have the backing of our investors as we move closer to providing effective solutions for obesity and diabetes management,” says Sana Alajmovic, Sigrid’s Co-Founder and CEO.

“Sigrid’s continued success is evident from the launch of one of the world’s largest prediabetes trial, SHINE, to SiPore21®’s medical device classification and the commercial traction in our oral health vertical. These accomplishments show the company is well on track to deliver on its exciting potential,” adds Mattias Ankarberg, Sigrid’s Chairman. 

“We’re pleased that Sigrid Therapeutics’ recent share offering was oversubscribed by an impressive 50%. In today’s challenging financial climate, this achievement underscores the company’s quality and potential. Amidst concerns about obesity and diabetes, the demand for effective, non-drug therapies is evident. This success mirrors investor confidence and Sigrid’s commitment to pioneering drug-free solutions,” adds Lars Molinder, financial adviser to Sigrid Therapeutics.

For more information, www.sigridthx.com, or please contact:

Sana Alajmovic, Co-Founder & CEO, Sigrid Therapeutics
Phone +46 72 389 3396
Email: [email protected]

Mattias Ankarberg, Chairman, Sigrid Therapeutics
Phone +46 70 796 3831
Email: [email protected]

Lars Molinder
Financial adviser
Phone +46 73 417 85 69 

About Sigrid Therapeutics

Sigrid Therapeutics is a Swedish impact unicorn dedicated to revolutionizing obesity and diabetes management through its innovative SiPore® technology. The company’s flagship product, SiPore21®, is currently in SHINE clinical trials, offering a natural, non-drug solution for prediabetes progression and weight control. With a focus on impactful innovation, Sigrid Therapeutics is committed to enhancing the well-being of individuals worldwide.

Logo – https://mma.prnewswire.com/media/2071527/4369715/Sigrid_Therapeutics_Logo.jpg

SOURCE Sigrid Therapeutics

ALTANTA , Oct. 30, 2023 — Fanbase, the ad-free social media platform that allows users to monetize their content and connect with their audience through various media features, announces that its current equity crowdfunding round has successfully crossed $4.50 million. This brings the total amount raised by Fanbase to $10 million.

This will be the third seed round for the general public to invest in Fanbase. Fanbase utilizes Startengine for Equity Crowdfunding to reinforce Fanbase’s unwavering commitment to promoting equality and inclusivity in the realm of social media, especially for historically marginalized communities.

Founded by Isaac Hayes III, son of the famed Iconic Soul Icon, Isaac Hayes. Isaac’s mission is to enable users to freely reach the entire social audience & democratize social media for all. That’s why the company’s brand promise is proudly “Be You. Without Limits.” 

“Equity crowdfunding is our way of inviting the Fanbase community to own a piece of the platform they believe in. We’re not just building a product; we’re growing a community- driven ecosystem where every voice, every creator, and every supporter shares in our collective success.” – Isaac Hayes III

This vision underpins Fanbase’s objective of empowering users and providing them with a platform where their voices can truly be heard.

Fanbase has an innovative approach to social media monetization for users. Users can engage with a range of media features, including photo/video, audio chat, live streaming, stories, short-form, and long-form video. Fanbase offers the option for users to subscribe to each other through in-app purchases, fostering creativity and enabling all users to monetize their work directly via their Fanbase profiles. Fanbase distinguishes itself through its affordability and inclusivity. The app is free to download and use, allowing anyone to create a profile, build a following, and connect with others. 

Fanbase further extends their brand promise by taking advantage of the Obama administration’s passed legislation, “The JOBS Act” .This allows main street small businesses and high-growth enterprises to raise capital from retail citizen investors more efficiently. Allowing small and young firms across the country to grow and hire faster, as well as giving everyday citizens the opportunity to invest in small startups.

Equity crowdfunding provides a unique opportunity for businesses to turn their customers into owners and create a more loyal user base ready to promote the business.

Waking up every day dedicated to improving the Fanbase user experience the funds raised in this successful equity crowdfunding round will be directed towards Fanbase’s expansion and development initiatives. These funds will enhance user experience, enhance creator tools, improve platform features, and expand marketing efforts to reach a wider audience.

Fanbase Social Media extends an open invitation to all to join them in their mission to reshape the social media landscape, champion diversity, and ensure that every voice is heard.

• To learn more about Fanbase Social Media, please visit their website athttps://www.fanbase.app/. 
• To Download the Fanbase application click here [insert dynamic link] 
• To learn more about Fanbase StartEngine crowdfunding campaign click here 

About Fanbase:

Fanbase, founded by Isaac Hayes III, is a new frontier of social media, placing monetization capability at the forefront to the benefit of all users. Rooted in community with the belief that “Everyone is a Fan of Something, And Everyone Has a Fanbase”, the social network is the first native app with full content monetization via photo, audio chat, lives, stories and both short and long-form video content. Users join, follow and like for free. Digital currency called “Love” as well as monthly subscriptions to exclusive content enables fans to reward their favorite creators. Fanbase is available on IOS and Android in 190+ countries worldwide. For more information, visit fanbase.app.

MEDIA CONTACT: 

Noah Washington

[email protected]

SOURCE Fanbase Social Media Inc.